(NASDAQ: PSTV) Plus Therapeutics's forecast annual revenue growth rate of 105.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.43%.
Plus Therapeutics's revenue in 2026 is $5,258,000.On average, 6 Wall Street analysts forecast PSTV's revenue for 2026 to be $912,391,496, with the lowest PSTV revenue forecast at $538,721,896, and the highest PSTV revenue forecast at $1,482,447,216. On average, 5 Wall Street analysts forecast PSTV's revenue for 2027 to be $3,069,752,802, with the lowest PSTV revenue forecast at $2,046,043,771, and the highest PSTV revenue forecast at $4,040,414,217.
In 2028, PSTV is forecast to generate $6,499,982,014 in revenue, with the lowest revenue forecast at $5,410,032,179 and the highest revenue forecast at $7,936,527,926.